Research Paper Volume 12, Issue 9 pp 8565—8582

Implications of maraviroc and/or rapamycin in a mouse model of fragility

Figure 5. Muscle expression of IL-1β, IL6, IL-18, TNF-α, CCR5 and CCL5 at the RNA level. (A) No differences were observed after analyzing IL-1β. (B) IL-6 expression was significantly lower in the MVC+RAPA group. (C) Although IL-18 expression was lower in all the therapeutic groups, it was only statistically significant in the MVC group. (D) Although TNF-α and (E) CCR5 expression were lower in all the therapeutic groups, none of them was statistically significant. (F) CCL5 expression was significantly lower in the MVC group and showed a clear tendency to statistical significance in the RAPA and MVC-RAPA group. Each bar represents the mean ± SEM. *p <0.05 with respect to control. IL, interleukin. MVC, maraviroc. MVC+RAPA, maraviroc plus rapamycin. RAPA, rapamycin. TNF-α, tumor necrosis factor-alpha.